A rare and severe side effect of liraglutide is the development of thyroid cancer
These factors can make a meaningful difference when selecting products for ongoing research projects
GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Eleven percent had treated diabetes, 20% were on therapy for obstructive sleep apnea (OSAS), 30% were treated for hypertension, 11% had managed dyslipidemia, 23% reported arthralgia, and 22% had hepatopathy
What is Henry Meds
The type of SGLT2 must also be assessed prior to starting as Empagliflozin so far has been associated with heart-health benefits and Canagliflozin with kidney protection in those without damage